Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Inovio Pharmaceuticals Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.7, while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). Which is the better fit depends on your goals.

BOILINO
Sector
Leveraged / InverseHealth
52-Week High
$87.24$2.87
52-Week Low
$18.74$0.66
Market Cap
$78.55M
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $20.73, showing minimal daily movement with a 0.1% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $21 with support at $20. Recent corporate actions include a 1:2 stock split scheduled for May 28, 2026. Natural gas market volatility and weather-dependent demand continue to influence price movements.

The outlook remains cautious given bearish technical signals and natural gas market uncertainty. Investment opportunities exist for tactical traders during volatility spikes, but risks include weather-dependent demand fluctuations and production increases. The stock split may improve liquidity but doesn't alter fundamental valuation. Investors should monitor EIA storage reports and weather forecasts as key catalysts.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO